- NCIt
- C8101
Loading cancer entity…
Loading cancer entity…
Clinical trials
1,164 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00036790 | Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer | completed | Phase 1 | — | University of Wisconsin, MadisonOTHER | 1 | Dec 17, 2019 | clinicaltrials |
| NCT01326702 | Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors | completed | Phase 1 / Phase 2 | 43 | National Cancer Institute (NCI)NIH | 1 | Dec 16, 2019 | clinicaltrials |
| NCT00004872 | Endostatin in Treating Patients With Advanced Refractory Solid Tumors | completed | Phase 1 | — | University of Wisconsin, MadisonOTHER | 1 | Dec 13, 2019 | clinicaltrials |
| NCT00005794 | Perifosine in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | — | University of Wisconsin, MadisonOTHER | 1 | Dec 13, 2019 | clinicaltrials |
| NCT00023855 | PS-341 and Doxorubicin in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | — | University of Wisconsin, MadisonOTHER | 1 | Dec 13, 2019 | clinicaltrials |
| NCT00049712 | Monoclonal Antibody Therapy in Treating Patients With Refractory Advanced Solid Tumors or Lymphoma | completed | Phase 1 | — | University of Wisconsin, MadisonOTHER | 1 | Dec 13, 2019 | clinicaltrials |
| NCT02146222 | VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Docetaxel in Treating Patients With Solid Tumors | completed | Phase 1 | 14 | University of Wisconsin, MadisonOTHER | 1 | Nov 18, 2019 | clinicaltrials |
| NCT00002677 | Tributyrin in Treating Patients With Refractory Prostate Cancer or Other Solid Tumors | completed | Phase 1 | 24 | University of Maryland, BaltimoreOTHER | 1 | Nov 4, 2019 | clinicaltrials |
| NCT01806675 | 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy | completed | Phase 1 / Phase 2 | 25 | Sanjiv Sam GambhirOTHER | 1 | Oct 3, 2019 | clinicaltrials |
| NCT03081819 | A Phase I Study of SH003 for Evaluate Safe Dose Range in Patients With Solid Cancer | completed | Phase 1 | 11 | Kyunghee University Medical CenterOTHER | 1 | Sep 11, 2019 | clinicaltrials |
| NCT02324621 | Continuation of Oral ONC201 in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 26 | Rutgers, The State University of New JerseyOTHER | 1 | May 22, 2019 | clinicaltrials |
| NCT03175497 | Telatinib Safety and Pharmacokinetics Study in China Patients With Advanced Solid Tumors | completed | Phase 1 | 15 | Taizhou EOC Pharma Co., Ltd.INDUSTRY | 1 | May 13, 2019 | clinicaltrials |
| NCT01791088 | Sirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery | completed | Phase 1 | 56 | University of ChicagoOTHER | 1 | Apr 22, 2019 | clinicaltrials |
| NCT00909831 | Hydroxychloroquine and Temsirolimus in Treating Patients With Metastatic Solid Tumors That Have Not Responded to Treatment | completed | Phase 1 | 40 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Apr 16, 2019 | clinicaltrials |
| NCT00390000 | Vatalanib and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 29 | Mayo ClinicOTHER | 1 | Apr 8, 2019 | clinicaltrials |
| NCT01537107 | Sirolimus and Vismodegib in Treating Patients With Solid Tumors or Pancreatic Cancer That is Metastatic or Cannot Be Removed By Surgery | completed | Phase 1 | 31 | Mayo ClinicOTHER | 1 | Apr 8, 2019 | clinicaltrials |
| NCT02717572 | 18F-FDG Uptake Measurements in Malignant Solid Tumors on PET/CT and PET/MR | completed | Phase 1 | 19 | Washington University School of MedicineOTHER | 1 | Apr 5, 2019 | clinicaltrials |
| NCT00002902 | Irinotecan Plus ICI D1694 in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | — | Abramson Cancer Center at Penn MedicineOTHER | 1 | Mar 13, 2019 | clinicaltrials |
| NCT01713972 | Dabrafenib and Pazopanib Hydrochloride in Treating Patients With Advanced Malignant Tumors | completed | Phase 1 | 23 | Manisha ShahOTHER | 1 | Mar 1, 2019 | clinicaltrials |
| NCT00711243 | Docetaxel, Oxaliplatin, and Fluorouracil in Treating Patients With Metastatic or Unresectable Stomach Cancer, Gastroesophageal Junction Cancer, or Other Solid Tumor | completed | Phase 1 / Phase 2 | 59 | Northwestern UniversityOTHER | 1 | Feb 26, 2019 | clinicaltrials |
| NCT00892385 | Methoxyamine and Temozolomide in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 66 | Case Comprehensive Cancer CenterOTHER | 1 | Feb 22, 2019 | clinicaltrials |
| NCT00547677 | Stereotactic Radiosurgery for Patients With Hepatic Metastases. | completed | Phase 1 | 27 | University of Texas Southwestern Medical CenterOTHER | 1 | Feb 15, 2019 | clinicaltrials |
| NCT00005639 | Azacitidine Plus Phenylbutyrate in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Previous Treatment | completed | Phase 1 | 34 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jan 11, 2019 | clinicaltrials |
| NCT01923337 | Irinotecan and Alisertib in Treating Patients With Advanced Solid Tumors or Colorectal Cancer | completed | Phase 1 | 17 | University of California, DavisOTHER | 1 | Jan 4, 2019 | clinicaltrials |
| NCT00390429 | Docetaxel and Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors | completed | Phase 1 / Phase 2 | 81 | University of California, DavisOTHER | 1 | Dec 6, 2018 | clinicaltrials |
| NCT01332721 | Study of TRC105 Combined With Standard-Dose Bevacizumab for Advanced Solid Tumors for Which Bevacizumab is Indicated | completed | Phase 1 | 38 | Tracon Pharmaceuticals Inc.INDUSTRY | 1 | Dec 5, 2018 | clinicaltrials |
| NCT00096317 | Ixabepilone and Ketoconazole in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 29 | Montefiore Medical CenterOTHER | 1 | Oct 31, 2018 | clinicaltrials |
| NCT00389805 | Bortezomib and Pemetrexed Disodium in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors | completed | Phase 1 / Phase 2 | 27 | University of California, DavisOTHER | 1 | Oct 31, 2018 | clinicaltrials |
| NCT00005807 | Treating Patients With Advanced Solid Tumors, Breast Cancer or Recurrent Ovarian Cancer(BMS-247550) | completed | Phase 1 | 40 | Albert Einstein College of MedicineOTHER | 1 | Oct 9, 2018 | clinicaltrials |
| NCT00410553 | Eribulin Mesylate and Gemcitabine Hydrochloride in Treating Patients With Metastatic Solid Tumors or Solid Tumors That Cannot be Removed by Surgery | completed | Phase 1 | 45 | National Cancer Institute (NCI)NIH | 1 | Oct 3, 2018 | clinicaltrials |
| NCT00004863 | Paclitaxel and GEM 231 in Treating Patients With Recurrent or Refractory Solid Tumors | completed | Phase 1 | 18 | Montefiore Medical CenterOTHER | 1 | Sep 10, 2018 | clinicaltrials |
| NCT00004864 | Docetaxel and GEM 231 in Treating Patients With Recurrent or Refractory Solid Tumors | completed | Phase 1 | — | Montefiore Medical CenterOTHER | 1 | Sep 10, 2018 | clinicaltrials |
| NCT00003713 | Chemotherapy in Treating Patients With Advanced or Metastatic Solid Tumors | completed | Phase 1 | 35 | Genzyme, a Sanofi CompanyINDUSTRY | 2 | Aug 29, 2018 | clinicaltrials |
| NCT00003822 | SR-45023A in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 30 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Aug 29, 2018 | clinicaltrials |
| NCT00004049 | SR-45023A in Treating Patients With Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 | 36 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Aug 29, 2018 | clinicaltrials |
| NCT02166255 | APN401 in Treating Patients With Melanoma, Kidney Cancer, Pancreatic Cancer, or Other Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery | completed | Phase 1 | 17 | Wake Forest University Health SciencesOTHER | 1 | Jul 3, 2018 | clinicaltrials |
| NCT00074308 | Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers | completed | Phase 1 / Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Jun 20, 2018 | clinicaltrials |
| NCT00837928 | Bendamustine and Radiation Therapy in Treating Patients With Brain Metastases Caused by Solid Tumors | completed | Phase 1 | 18 | John GreculaOTHER | 1 | May 17, 2018 | clinicaltrials |
| NCT01042535 | Vaccine Therapy and 1-MT in Treating Patients With Metastatic Breast Cancer | completed | Phase 1 / Phase 2 | 44 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 11, 2018 | clinicaltrials |
| NCT00290680 | Bortezomib and Celecoxib in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 36 | Medical University of South CarolinaOTHER | 1 | Apr 10, 2018 | clinicaltrials |
| NCT00334789 | Belinostat and Isotretinoin in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery | completed | Phase 1 | 51 | National Cancer Institute (NCI)NIH | 1 | Apr 3, 2018 | clinicaltrials |
| NCT01654965 | Tivantinib and Topotecan Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors | completed | Phase 1 | 17 | National Cancer Institute (NCI)NIH | 1 | Apr 3, 2018 | clinicaltrials |
| NCT00014261 | Temozolomide Plus PEG-Interferon Alfa-2B in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | — | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Mar 30, 2018 | clinicaltrials |
| NCT00825201 | Intraperitoneal Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Cancer of the Peritoneal Cavity | completed | Phase 1 | 27 | City of Hope Medical CenterOTHER | 1 | Jan 19, 2018 | clinicaltrials |
| NCT00033241 | Erlotinib Combined With Gemcitabine in Treating Patients With Newly Diagnosed Locally Advanced or Metastatic Pancreatic Cancer or Other Solid Tumors | completed | Phase 1 | — | OSI PharmaceuticalsINDUSTRY | 1 | Jan 10, 2018 | clinicaltrials |
| NCT02194049 | Cisplatin, Etoposide and PI3K Inhibitor BKM120 in Treating Patients With Advanced Solid Tumors or Small Cell Lung Cancer | completed | Phase 1 | 3 | University of California, DavisOTHER | 1 | Jan 9, 2018 | clinicaltrials |
| NCT00098514 | Talotrexin in Treating Patients With Advanced or Recurrent Solid Tumors | completed | Phase 1 | 53 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 18, 2017 | clinicaltrials |
| NCT00622674 | Bortezomib and Cetuximab in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 37 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 2, 2017 | clinicaltrials |
| NCT01264432 | Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal Cancer | completed | Phase 1 | 34 | National Cancer Institute (NCI)NIH | 2 | Nov 21, 2017 | clinicaltrials |
| NCT00389584 | Irinotecan and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases From Solid Tumors | completed | Phase 1 / Phase 2 | 30 | University of California, DavisOTHER | 1 | Nov 6, 2017 | clinicaltrials |
Data updated 23 days agoSource updated Dec 17, 2019source: clinicaltrials